rhTSH Noninferior to Hormone Withdrawal for RAI Ablation in Intermediate-Risk Thyroid Cancer
An open-label phase 3 noninferiority trial finds recombinant human thyrotropin matches thyroid hormone withdrawal for radioactive iodine ablation success in intermediate-risk differentiated thyroid cancer, with fewer adverse events. PICO summary and expert commentary.
